이 페이지의 번역은 실험적이며 개발 중입니다. 여러분의 환영합니다!

Lee's Pharmaceutical Holdings 관리

관리 기준 확인 2/4

현재 CEO에 대한 정보가 충분하지 않습니다.

주요 정보

최고 경영자

n/a

총 보상

CEO 급여 비율	n/a
CEO 임기	no data
CEO 소유권	n/a
경영진 평균 재임 기간	9.8yrs
이사회 평균 재임 기간	11.2yrs

최근 관리 업데이트

Recent updates

Lee's Pharmaceutical Holdings (HKG:950) Has Affirmed Its Dividend Of HK$0.01

May 21

Optimistic Investors Push Lee's Pharmaceutical Holdings Limited (HKG:950) Shares Up 28% But Growth Is Lacking

Dec 20

Can Mixed Fundamentals Have A Negative Impact on Lee's Pharmaceutical Holdings Limited (HKG:950) Current Share Price Momentum?

Mar 17

Should You Buy Lee's Pharmaceutical Holdings Limited (HKG:950) For Its 0.9% Dividend?

Feb 22

What Type Of Returns Would Lee's Pharmaceutical Holdings'(HKG:950) Shareholders Have Earned If They Purchased Their SharesThree Years Ago?

Jan 29

What Type Of Shareholders Own The Most Number of Lee's Pharmaceutical Holdings Limited (HKG:950) Shares?

Jan 12

Have Insiders Sold Lee's Pharmaceutical Holdings Limited (HKG:950) Shares Recently?

Dec 22

Don't Ignore The Fact That This Insider Just Sold Some Shares In Lee's Pharmaceutical Holdings Limited (HKG:950)

Dec 08

Is Lee's Pharmaceutical Holdings Limited's (HKG:950) Recent Price Movement Underpinned By Its Weak Fundamentals?

Dec 01

Is Lee's Pharmaceutical Holdings Limited (HKG:950) A Strong Dividend Stock?

Nov 18

CEO

Lee's Pharmaceutical Holdings 에는 CEO가 없거나 그에 대한 데이터가 없습니다.

리더십 팀

이름	위치	테뉴어	보상	소유권
Siu Fong Lee	Chairman & Compliance Officer	no data	HK$12.18m	0.14% HK$ 921.0k
Xiaoyi Li	Founder	3.3yrs	HK$6.54m	9.99% HK$ 67.6m
Wanee Leelalertsuphakun	MD, Chief Marketing & Sales Officer and Executive Director	20.8yrs	HK$13.20m	1.28% HK$ 8.7m
Yiu Ming Chow	Group CFO & Company Secretary	9.8yrs	데이터 없음	데이터 없음
Yueshen Chen	Director of Administration in China	no data	데이터 없음	데이터 없음
Tsui Victor Kailok	Group Chief Manufacturing Officer	12.5yrs	데이터 없음	데이터 없음
Yuanjue Sun	Chief Medical Officer	2.8yrs	데이터 없음	데이터 없음
Zhongyu Jiao	Group Deputy GM & GM of the Risk Control Centre	no data	데이터 없음	데이터 없음

9.8yrs

평균 재임 기간

61yo

평균 연령

경험이 풍부한 관리: 950 의 관리팀은 노련하고 경험 (평균 재직 기간 9.7 년)입니다.

이사회 구성원

이름	위치	테뉴어	보상	소유권
Siu Fong Lee	Chairman & Compliance Officer	no data	HK$12.18m	0.14% HK$ 921.0k
Xiaoyi Li	Founder	no data	HK$6.54m	9.99% HK$ 67.6m
Wanee Leelalertsuphakun	MD, Chief Marketing & Sales Officer and Executive Director	no data	HK$13.20m	1.28% HK$ 8.7m
James Gale	Non-Executive Director	2.5yrs	HK$300.00k	데이터 없음
Yau Ching Chan	Independent Non-Executive Director	22.5yrs	HK$216.00k	0.088% HK$ 598.0k
Wah Keung Tsim	Independent Non-Executive Director	19.8yrs	HK$216.00k	0.051% HK$ 345.0k
Yee Wah Cheang	Independent Non Executive Director	1.2yrs	HK$135.00k	데이터 없음

11.2yrs

평균 재임 기간

65yo

평균 연령

경험이 풍부한 이사회: 950 의 이사회는 노련하고 경험이 있습니다(평균 재직 기간 11.1 년).

Lee's Pharmaceutical Holdings 관리

관리 기준 확인 2/4

주요 정보

최근 관리 업데이트

Lee's Pharmaceutical Holdings Limited Appoints Huang Zuie Chin as A Non-Executive Director

Board Member recently bought HK$120k worth of stock

Board Member recently bought HK$61k worth of stock

Board Member recently bought HK$130k worth of stock

Less than half of directors are independent

Lee's Pharmaceutical Holdings Limited, Annual General Meeting, May 22, 2024

Recent updates

Lee's Pharmaceutical Holdings Limited Appoints Huang Zuie Chin as A Non-Executive Director

Board Member recently bought HK$120k worth of stock

Board Member recently bought HK$61k worth of stock

Lee's Pharmaceutical Holdings (HKG:950) Has Affirmed Its Dividend Of HK$0.01

Upcoming dividend of HK$0.01 per share

Board Member recently bought HK$130k worth of stock

Less than half of directors are independent

Final dividend of HK$0.01 announced

Lee's Pharmaceutical Holdings Limited, Annual General Meeting, May 22, 2024

Full year 2023 earnings released: EPS: HK$0.028 (vs HK$0.087 in FY 2022)

Lee's Pharmaceutical Holdings Limited Proposes Ordinary Final Dividend for the Year Ended 31 December 2023, Payable on 17 June 2024

Lee's Pharmaceutical Holdings Limited to Report Fiscal Year 2023 Results on Mar 26, 2024

Board Member recently bought HK$123k worth of stock

New minor risk - Market cap size

Board Member recently bought HK$75k worth of stock

Investor sentiment improves as stock rises 15%

Optimistic Investors Push Lee's Pharmaceutical Holdings Limited (HKG:950) Shares Up 28% But Growth Is Lacking

Investor sentiment improves as stock rises 18%

Board Member recently bought HK$50k worth of stock

Board Member recently bought HK$113k worth of stock

Senior Adviser & Non-Executive Director recently bought HK$347k worth of stock

Investor sentiment improves as stock rises 17%

Senior Adviser & Non-Executive Director recently bought HK$110k worth of stock

Senior Adviser & Non-Executive Director recently bought HK$76k worth of stock

Investor sentiment improves as stock rises 18%

Price target decreased by 55% to HK$1.10

Lee's Pharmaceutical Holdings Limited Announces Interim Dividend for the Six Months Ended June 30, 2023, Payable on 04 October 2023

First half 2023 earnings released: EPS: HK$0.027 (vs HK$0.048 in 1H 2022)

New minor risk - Market cap size

Lee's Pharmaceutical Holdings Limited Provides Earnings Guidance for the Six Months Ended 30 June 2023

Lee's Pharmaceutical Holdings Limited to Report First Half, 2023 Results on Aug 30, 2023

Lee's Pharmaceutical Holdings' (HKG:950) Dividend Is Being Reduced To HK$0.01

Lee's Pharmaceutical Holdings Limited Appoints Cheang Yee Wah, Eva as Independent Non-Executive Director

Upcoming dividend of HK$0.01 per share at 1.3% yield

Lee's Pharmaceutical Holdings' (HKG:950) Dividend Is Being Reduced To HK$0.01

Full year 2022 earnings released: EPS: HK$0.087 (vs HK$3.38 in FY 2021)

Lee's Pharmaceutical Holdings Limited Announces Inclusion of Treprostinil Injection, Teglutik and Trittico in the National Reimbursement Drug List

Third quarter 2022 earnings released: EPS: HK$0.058 (vs HK$0.024 in 3Q 2021)

Price target decreased to HK$1.80

Less than half of directors are independent

Lee's Pharmaceutical Holdings Limited to Report Q3, 2022 Results on Nov 17, 2022

Lee's Pharmaceutical Holdings Limited Announces Completion of Patient Enrolment for A Phase III Clinical Trial of Intrarosa

Price target decreased to HK$1.80

Upcoming dividend of HK$0.01 per share

Lee's Pharmaceutical Holdings' (HKG:950) Dividend Is Being Reduced To HK$0.01

Lee's Pharmaceutical Holdings Limited Announces Interim Dividend for the Six Months Ended June 30, 2022, Payable on September 27, 2022

Second quarter 2022 earnings released: EPS: HK$0.014 (vs HK$3.59 in 2Q 2021)

Lee's Pharmaceutical Holdings Limited to Report First Half, 2022 Results on Aug 26, 2022

Lee's Pharmaceutical Holdings Limited Provides Earnings Guidance for the Six Months Ended 30 June 2022

Board Member recently bought HK$231k worth of stock

Lee's Pharmaceutical Holdings Limited Announces That Teglutik Obtains Drug Registration Certificate

Board Member recently bought HK$381k worth of stock

First quarter 2022 earnings released: EPS: HK$0.035 (vs HK$0.07 in 1Q 2021)

Lee's Pharmaceutical Holdings Limited's Natulan Obtains Drug Registration Certificate

Upcoming dividend of HK$0.031 per share

Lee's Pharmaceutical Holdings Limited to Report Q1, 2022 Results on May 26, 2022

Price target decreased to HK$4.85

Less than half of directors are independent

Lee's Pharmaceutical Holdings Limited, Annual General Meeting, May 19, 2022

Full year 2021 earnings released: EPS: HK$3.38 (vs HK$0.22 in FY 2020)

Lee's Pharmaceutical Holdings Limited Proposes Final Dividend for the Year Ended 31 December 2021, Payable on 15 June 2022

Price target decreased to HK$5.30

Third quarter 2021 earnings: Revenues and EPS in line with analyst expectations

Lee's Pharmaceutical Holdings Limited Obtains Approval from the Center for Drug Evaluation

Second quarter 2021 earnings released: EPS HK$3.59 (vs HK$0.097 in 2Q 2020)

Investor sentiment deteriorated over the past week

Non-Executive Director Simon Miles Ball has left the company

Price target decreased to HK$6.42

First quarter 2021 earnings released: EPS HK$0.07 (vs HK$0.068 in 1Q 2020)